173 related articles for article (PubMed ID: 29517862)
1. Safety, Tolerability, and Pharmacokinetics of 3 g of Ceftolozane/Tazobactam in Healthy Adults: A Randomized, Placebo-Controlled, Multiple-Dose Study.
Yu B; Adedoyin A; Hershberger E; Caro L; Xiao A; Rhee EG; Huntington JA
Clin Pharmacol Drug Dev; 2018 May; 7(4):382-391. PubMed ID: 29517862
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Safety of Single Intravenous Doses of Ceftolozane/Tazobactam in Children With Proven or Suspected Gram-Negative Infection.
Bradley JS; Ang JY; Arrieta AC; Larson KB; Rizk ML; Caro L; Yang S; Yu B; Johnson MG; Rhee EG
Pediatr Infect Dis J; 2018 Nov; 37(11):1130-1136. PubMed ID: 30153232
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Tissue Penetration of Ceftolozane-Tazobactam in Diabetic Patients with Lower Limb Infections and Healthy Adult Volunteers.
Monogue ML; Stainton SM; Baummer-Carr A; Shepard AK; Nugent JF; Kuti JL; Nicolau DP
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893779
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, safety, and tolerability of ceftolozane/tazobactam in healthy Japanese, Chinese, and white subjects.
Aiudi A; Miller B; Krishna G; Adedoyin A; Xiao A
Fundam Clin Pharmacol; 2016 Dec; 30(6):625-633. PubMed ID: 27473285
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance.
Nicolau DP; De Waele J; Kuti JL; Caro L; Larson KB; Yu B; Gadzicki E; Zeng Z; Rhee EG; Rizk ML
Int J Antimicrob Agents; 2021 Apr; 57(4):106299. PubMed ID: 33567333
[TBL] [Abstract][Full Text] [Related]
6. A single- and multiple-dose study to characterize the pharmacokinetics, safety, and tolerability of ceftolozane/tazobactam in healthy Chinese participants.
Liu N; Wang X; Zhu J; Basu S; Wei Y; Yan B; Wang H; Colon-Gonzalez F; Feng HP; Sun F; Li H; Zang Y
Int J Antimicrob Agents; 2023 Mar; 61(3):106717. PubMed ID: 36640850
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of tazobactam/ceftolozane in Japanese patients with complicated urinary tract infection and complicated intra-abdominal infection.
Kakara M; Larson K; Feng HP; Shiomi M; Yoshitsugu H; Rizk ML
J Infect Chemother; 2019 Mar; 25(3):182-191. PubMed ID: 30528208
[TBL] [Abstract][Full Text] [Related]
8. Ceftolozane-tazobactam for the treatment of multidrug-resistant
Alessa MA; Almangour TA; Alhossan A; Alkholief MA; Alhokail M; Tabb DE
Am J Health Syst Pharm; 2018 May; 75(9):e184-e188. PubMed ID: 29691260
[TBL] [Abstract][Full Text] [Related]
9. Ceftolozane/Tazobactam in Neonates and Young Infants: The Challenges of Collecting Pharmacokinetics and Safety Data in This Vulnerable Patient Population.
Ang JY; Arrieta A; Bradley JS; Zhang Z; Yu B; Rizk ML; Johnson MG; Rhee EG
Am J Perinatol; 2021 Jul; 38(8):804-809. PubMed ID: 31910460
[TBL] [Abstract][Full Text] [Related]
10. Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection.
Noel AR; Bowker KE; Attwood M; MacGowan AP
J Antimicrob Chemother; 2018 Sep; 73(9):2411-2417. PubMed ID: 30020472
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation.
Monogue ML; Pettit RS; Muhlebach M; Cies JJ; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2016 Nov; 60(11):6578-6584. PubMed ID: 27550351
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction.
Sime FB; Lassig-Smith M; Starr T; Stuart J; Pandey S; Parker SL; Wallis SC; Lipman J; Roberts JA
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358583
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses.
Miller B; Hershberger E; Benziger D; Trinh M; Friedland I
Antimicrob Agents Chemother; 2012 Jun; 56(6):3086-91. PubMed ID: 22450972
[TBL] [Abstract][Full Text] [Related]
14. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).
Solomkin J; Hershberger E; Miller B; Popejoy M; Friedland I; Steenbergen J; Yoon M; Collins S; Yuan G; Barie PS; Eckmann C
Clin Infect Dis; 2015 May; 60(10):1462-71. PubMed ID: 25670823
[TBL] [Abstract][Full Text] [Related]
15. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects.
Chandorkar G; Huntington JA; Gotfried MH; Rodvold KA; Umeh O
J Antimicrob Chemother; 2012 Oct; 67(10):2463-9. PubMed ID: 22773741
[TBL] [Abstract][Full Text] [Related]
16. Plasma pharmacokinetics of ceftolozane/tazobactam in pediatric patients with cystic fibrosis.
Arrieta AC; Ang JY; Zhang Z; Larson KB; Yu B; Johnson MG; Rhee EG; Feng EH; Rizk ML
Pediatr Pulmonol; 2020 Aug; 55(8):2025-2032. PubMed ID: 32421928
[TBL] [Abstract][Full Text] [Related]
17. Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated Intra-abdominal Infections.
Larson KB; Patel YT; Willavize S; Bradley JS; Rhee EG; Caro L; Rizk ML
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962340
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetic Analysis for Plasma and Epithelial Lining Fluid Ceftolozane/Tazobactam Concentrations in Patients With Ventilated Nosocomial Pneumonia.
Zhang Z; Patel YT; Fiedler-Kelly J; Feng HP; Bruno CJ; Gao W
J Clin Pharmacol; 2021 Feb; 61(2):254-268. PubMed ID: 32949031
[TBL] [Abstract][Full Text] [Related]
19. A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration.
Sime FB; Lassig-Smith M; Starr T; Stuart J; Pandey S; Parker SL; Wallis SC; Lipman J; Roberts JA
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31658965
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects.
Saisho Y; Katsube T; White S; Fukase H; Shimada J
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
